Asthma in the spotlight as Upstream Bio starts trial and UK universities propose new long-term treatment - Labiotech.eu

Upstream Bio has initiated a phase 1b study of UPB-101 in asthma patients with the dosing of the first patient.

Upstream Bio, a clinical-stage biotech company advancing new therapies to treat inflammation, has initiated a phase 1b multiple ascending dose study of UPB-101 in asthma patients with the dosing of t… [+5712 chars]

full article...